EirGenix Inc. announced that the Board of Directors resolved to sign the contract with clinical CRO and the relevant companies for Phase III clinical trail of the EG1206A. In accordance with the development schedule of self-development product EG1206A, this project will undergo Phase III clinical trials, and the board of directors has authorized the chairman to handle the contract signing with full authority. The total contract amount may affect the licensing deal during future global negotiations.

Therefore, it is not to be disclosed publicly to protect the company's and investors' rights and interests.